A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06988488)

🧪 Interventions in This Study

• Elranatamab (DRUG)
• Mezigdomide (DRUG)
• Dexamethasone (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• University of Alabama at Birmingham — Birmingham, Alabama
• Yale New Haven Hospital-Smilow Cancer Center — New Haven, Connecticut
• Hackensack University Medical Center — Hackensack, New Jersey
• University of Texas MD Anderson Cancer Center — Houston, Texas
• Arthur J E Child Comprehensive Cancer Centre — Calgary, Alberta
• Local Institution - 0026 — Vancouver, British Columbia
• QEII Health Sciences Centre - Victoria General Site — Halifax, Nova Scotia
• Princess Margaret Cancer Centre — Toronto, Ontario
• Local Institution - 0030 — Suzhou, Jiangsu
• Local Institution - 0031 — Shanghai, Shanghai Municipality
• Universitaetsklinikum Carl Gustav Carus Dresden — Dresden,
• Universitaetsklinikum Hamburg-Eppendorf — Hamburg,
• Universitaetsklinikum Heidelberg — Heidelberg,
• Evangelismos General Hospital of Athens — Athens, Attikí
• Alexandra General Hospital of Athens — Athens, Attikí
• St. Olavs Hospital — Trondheim, Sør-Trøndelag
• Sykehusapoteket Ull — Oslo,
• Hospital Universitario Marqués de Valdecilla — Santander, Cantabria
• Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca — Salamanca,
• University College London Hospital — London, England
• Royal Marsden Hospital (Sutton) — London, Sutton
• The Christie NHS Foundation Trust — Manchester,

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.